+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Pharmaceutical Contract Manufacturing and Research Services Market Size, Share & Trends Analysis Report by Service (Manufacturing, Research), by Region, and Segment Forecasts, 2022-2030

  • ID: 4312535
  • Report
  • April 2022
  • Region: Global
  • 180 Pages
  • Grand View Research

FEATURED COMPANIES

  • Abbvie, Inc.
  • Aenova Holding GmbH
  • Boehringer Ingelheim GmbH
  • Catalent Pharma Solutions
  • Covance, Inc. (Labcorp)
  • Grifols S.A
The global pharmaceutical contract manufacturing and research services market size is expected to reach USD 395.2 billion by 2030. It is expected to expand at a CAGR of 7.2% from 2022 to 2030. The rising investments in R&D, increasing demand for generics, and the growing aging population with various chronic diseases are responsible for market growth. However, the advent of COVID-19 led to a temporary shutdown of research and manufacturing activities of ancillary goods used for manufacturing drugs, which had impacted the supply chain and is likely to have a negative impact on the market growth.



Outsourcing allows pharmaceutical companies to focus on their core competencies such as sales and marketing rather than manufacturing and research. This is expected to have a positive impact on the market growth. However, the pharmaceutical companies practicing in-house manufacturing are increasing their investments with respect to production capabilities. This may limit the potential growth of contract manufacturing services to traditional customers, thereby hampering industrial growth.

The COVID-19 pandemic has provided new opportunities for pharmaceutical contract manufacturing and research services. Because of this pandemic, the contract service sector has switched its focus toward manufacturing and research of COVID-19 therapies and vaccines. For instance, in October 2020, CDMO Recipharm formed an agreement with Arcturus Therapeutics to support the manufacturing of its COVID-19 vaccine candidate-ARCT-021. Currently, it is in the phase 1/2 clinical trial. Similarly, in March 2022, the biotechnology company GeoVax partnered with a CRO CATO SMS to support GeoVAX in the Phase 2 trials of the COVID-19 Vaccine candidate GEO-CM04S1.

Pharmaceutical Contract Manufacturing and Research Services Market Report Highlights

  • by service, the manufacturing segment dominated the market in 2021. In this segment, Active Pharmaceutical Ingredient (API) / bulk drugs held the largest revenue share of over 60.0% in 2021. Pharmaceutical companies prefer outsourcing services for API research and manufacturing owing to the reduction in the cost of production of APIs.
  • In the manufacturing service segment, finished dose formulations are expected to register the fastest CAGR of 7.7% from 2022 to 2030.
  • The research service segment is further segmented based on therapeutic area, wherein oncology held a significant share of over 25.0% in 2021 and is anticipated to maintain its lead in the coming years owing to the high disease burden of cancer worldwide.
  • CMOs/CDMOs with the ability to establish facilities in emerging countries are expected to drive the market. The contract service sector is in its infancy in countries, including Brazil, India, and China.
  • Companies can position themselves for strong growth, given that demand is expected to expand rapidly in the coming years. Increased competitiveness in the contract service sector is anticipated to ultimately benefit the sector growth.
  • China, Japan, and India are projected to witness tremendous growth in the forecast period owing to high disease prevalence.
Frequently Asked Questions about the Global Pharmaceutical Contract Manufacturing and Research Services Market

What is the estimated value of the Global Pharmaceutical Contract Manufacturing and Research Services Market?

The Global Pharmaceutical Contract Manufacturing and Research Services Market was estimated to be valued at $226.6 Billion in 2022.

What is the growth rate of the Global Pharmaceutical Contract Manufacturing and Research Services Market?

The growth rate of the Global Pharmaceutical Contract Manufacturing and Research Services Market is 7.2%, with an estimated value of $395.2 Billion by 2030.

What is the forecasted size of the Global Pharmaceutical Contract Manufacturing and Research Services Market?

The Global Pharmaceutical Contract Manufacturing and Research Services Market is estimated to be worth $395.2 Billion by 2030.

Who are the key companies in the Global Pharmaceutical Contract Manufacturing and Research Services Market?

Key companies in the Global Pharmaceutical Contract Manufacturing and Research Services Market include Boehringer Ingelheim GmbH, Lonza, Grifols S.A, Jubilant Life Sciences Limited, Pfizer, Inc., Charles River Laboratories International, Inc, Albany Molecular Research, Inc., Covance, Inc. (Labcorp) and Baxter Biopharma Solutions.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Abbvie, Inc.
  • Aenova Holding GmbH
  • Boehringer Ingelheim GmbH
  • Catalent Pharma Solutions
  • Covance, Inc. (Labcorp)
  • Grifols S.A

Chapter 1 Methodology and Scope
1.1 Market Segmentation & Scope
1.1.1 Service
1.1.2 Regional Scope
1.1.3 Estimates and Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database
1.3.2 Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.3.5 Details Of Primary Research
1.4 Information or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis (Model 1)
1.6.2 Volume Price Analysis (Model 2)
1.7 List of Secondary Sources
1.8 List of Primary Sources
1.9 List of Abbreviations
1.10 Objectives
1.10.1 Objective-1
1.10.2 Objective-2
1.10.3 Objective-3
1.10.4 Objective-4
Chapter 2 Executive Summary
2.1 Market Outlook
Chapter 3 Pharmaceutical Contract Manufacturing & Research Market: Variables, Trends, & Scope
3.1 Market Segmentation and Scope
3.2 Market Driver Analysis
3.2.1 Drug shortage driving demand for pharmaceutical development
3.2.2 Commercial success of biologics for clinical use
3.2.3 Lower manufacturing costs and improving economic condition of BRIC
3.3 Market Restraint Analysis
3.3.1 Limited outsourcing opted by big pharma companies
3.3.2 Regulatory issues pertaining to the drug approval
3.4 Penetration & Growth Prospect Mapping
3.5 Porter’s Five Forces Analysis
3.6 PESTEL Analysis
3.7 COVID-19 Analysis
Chapter 4 Pharmaceutical Contract Manufacturing & Research Market: Services Segment Analysis
5.1 Pharmaceutical Contract Manufacturing & Research Market: Market Share Analysis, 2021 & 2030
5.2 Manufacturing
5.2.1 Manufacturing market, 2018-2030 (USD Billion)
5.2.2 API/Bulk Drugs
5.2.2.1 API/Bulk Drugs market, 2018-2030 (USD Billion)
5.2.3 Advanced Drug Delivery Formulations
5.2.3.1 Advanced Drug Delivery Formulations market, 2018-2030 (USD Billion)
5.2.4 Packaging
5.2.4.1 packaging market, 2018-2030 (USD Billion)
5.2.5 Finished Dose Formulations
5.2.5.1 Finished Dose Formulations market, 2018-2030 (USD Billion)
5.2.5.2 Solid
5.2.5.2.1 Solid market, 2018-2030 (USD Billion)
5.2.5.3 Liquid
5.2.5.3.1 Liquid market, 2018-2030 (USD Billion)
5.2.5.4 Semi-solid formulations
5.2.5.4.1 Semi-solid formulations market, 2018-2030 (USD Billion)
5.3 Research
5.3.1 Research market, 2018-2030 (USD Billion)
5.3.2 Oncology
5.3.2.1 Oncology market, 2018-2030 (USD Billion)
5.3.3 Vaccines
5.3.3.1 Vaccines market, 2018-2030 (USD Billion)
5.3.4 Inflammation & Immunology
5.3.4.1 Inflammation & Immunology market, 2018-2030 (USD Billion)
5.3.5 Cardiology
5.3.5.1 Cardiology market, 2018-2030 (USD Billion)
5.3.6 Neuroscience
5.3.6.1 Neuroscience market, 2018-2030 (USD Billion)
5.3.7 Others
5.3.7.1 Others market, 2018-2030 (USD Billion)
Chapter 6 Pharmaceutical Contract Manufacturing & Research Market: Regional Analysis
6.1 Pharmaceutical Contract Manufacturing & Research Market: Market Share Analysis, 2021 & 2030
6.2 North America
6.2.1 North America Pharmaceutical Contract Manufacturing & Research Market, 2018-2030 (USD Billion)
6.2.2 U.S.
6.2.2.1 U.S. Pharmaceutical Contract Manufacturing & Research Market, 2018-2030 (USD Billion)
6.2.3 Canada
6.2.3.1 Canada Pharmaceutical Contract Manufacturing & Research Market, 2018-2030 (USD Billion)
6.3 Europe
6.3.1 Europe Pharmaceutical Contract Manufacturing & Research Market, 2018-2030 (USD Billion)
6.3.2 Germany
6.3.2.1 Germany Pharmaceutical Contract Manufacturing & Research Market, 2018-2030 (USD Billion)
6.3.3 France
6.3.3.1 France Pharmaceutical Contract Manufacturing & Research Market, 2018-2030 (USD Billion)
6.3.4 Italy
6.3.4.1 Italy Pharmaceutical Contract Manufacturing & Research Market, 2018-2030 (USD Billion)
6.3.5 Spain
6.3.5.1 Spain Pharmaceutical Contract Manufacturing & Research Market, 2018-2030 (USD Billion)
6.3.6 U.K.
6.3.6.1 U.K. Pharmaceutical Contract Manufacturing & Research Market, 2018-2030 (USD Billion)
6.4 Asia Pacific
6.4.1 Asia Pacific Pharmaceutical Contract Manufacturing & Research Market, 2018-2030 (USD Billion)
6.4.2 China
6.4.2.1 China Pharmaceutical Contract Manufacturing & Research Market, 2018-2030 (USD Billion)
6.4.3 India
6.4.3.1 India Pharmaceutical Contract Manufacturing & Research Market, 2018-2030 (USD Billion)
6.4.4 Japan
6.4.4.1 Japan Pharmaceutical Contract Manufacturing & Research Market, 2018-2030 (USD Billion)
6.4.5 Australia
6.4.5.1 Australia Pharmaceutical Contract Manufacturing & Research Market, 2018-2030 (USD Billion)
6.5 Latin America
6.5.1 Latin America Pharmaceutical Contract Manufacturing & Research Market, 2018-2030 (USD Billion)
6.5.2 Brazil
6.5.2.1 Brazil Pharmaceutical Contract Manufacturing & Research Market, 2018-2030 (USD Billion)
6.5.3 Mexico
6.5.3.1 Mexico Pharmaceutical Contract Manufacturing & Research Market, 2018-2030 (USD Billion)
6.5.4 Argentina
6.5.4.1 Argentina Pharmaceutical Contract Manufacturing & Research Market, 2018-2030 (USD Billion)
6.5.5 Colombia
6.5.5.1 Colombia Pharmaceutical Contract Manufacturing & Research Market, 2018-2030 (USD Billion)
6.5.6 Chile
6.5.6.1 Chile Pharmaceutical Contract Manufacturing & Research Market, 2018-2030 (USD Billion)
6.5.7 VENEZUELA
6.5.7.1 venezuela Pharmaceutical Contract Manufacturing & Research Market, 2018-2030 (USD Billion)
6.6 MEA
6.6.1 MEA Pharmaceutical Contract Manufacturing & Research Market, 2018-2030 (USD Billion)
6.6.2 South Africa
6.6.2.1 South Africa Pharmaceutical Contract Manufacturing & Research Market, 2018-2030 (USD Billion)
6.6.3 Saudi Arabia
6.6.3.1 Saudi Arabia Pharmaceutical Contract Manufacturing & Research Market, 2018-2030 (USD Billion)
Chapter 7 Competitive Landscape
7.1 Strategy Framework
7.2 Market Participation Categorization
7.3 Company Profiles
7.3.1 Boehringer Ingelheim GmbH
7.3.1.1 Company overview
7.3.1.2 Financial performance
7.3.1.3 Product benchmarking
7.3.1.4 Strategic initiatives
7.3.2 Lonza
7.3.2.1 Company overview
7.3.2.2 Financial performance
7.3.2.3 Product benchmarking
7.3.2.4 Strategic initiatives
7.3.3 Grifols S.A
7.3.3.1 Company overview
7.3.3.2 Financial performance
7.3.3.3 Product benchmarking
7.3.3.4 Strategic initiatives
7.3.4 Jubilant Life Sciences Limited
7.3.4.1 Company overview
7.3.4.2 Financial performance
7.3.4.3 Product benchmarking
7.3.4.4 Strategic initiatives
7.3.5 Pfizer, Inc.
7.3.5.1 Company overview
7.3.5.2 Financial performance
7.3.5.3 Product benchmarking
7.3.5.4 Strategic initiatives
7.3.6 Charles River Laboratories International, Inc
7.3.6.1 Company overview
7.3.6.2 Financial performance
7.3.6.3 Product benchmarking
7.3.6.4 Strategic initiatives
7.3.7 Albany Molecular Research, Inc.
7.3.7.1 Company overview
7.3.7.2 Product benchmarking
7.3.7.3 Strategic initiatives
7.3.8 Covance, Inc. (LabCorp)
7.3.8.1 Company overview
7.3.8.2 Financial performance
7.3.8.3 Product benchmarking
7.3.9 IQVIA
7.3.9.1 Company overview
7.3.9.2 Financial performance
7.3.9.3 Product benchmarking
7.3.9.4 Strategic initiatives
7.3.10 Baxter BioPharma Solutions
7.3.10.1 Company overview
7.3.10.2 Financial performance
7.3.10.3 Product Benchmarking
7.3.10.4 Strategic initiatives
7.3.11 Aenova Holding GmbH
7.3.11.1 Company overview
7.3.11.2 Product Benchmarking
7.3.12 Vetter Pharma
7.3.12.1 Company Overview
7.3.12.2 Product benchmarking
7.3.13 Valeant Pharmaceuticals International Inc.
7.3.13.1 Company Overview
7.3.13.2 Financial performance
7.3.13.3 Product benchmarking
7.3.14 Ligand Pharmaceuticals, Inc.
7.3.14.1 Company Overview
7.3.14.2 Financial performance
7.3.14.3 Product benchmarking
7.3.14.4 Strategic initiatives
7.3.15 Pharmaceutical Product Development, LLC
7.3.15.1 Company Overview
7.3.15.2 Financial performance
7.3.15.3 Product benchmarking
7.3.15.4 Strategic initiatives
7.3.16 Recipharm AB.
7.3.16.1 Company Overview
7.3.16.2 Financial performance
7.3.16.3 Product benchmarking
7.3.16.4 Strategic initiatives
7.3.17 AbbVie, Inc.
7.3.17.1 Company Overview
7.3.17.2 Financial performance
7.3.17.3 Product benchmarking
7.3.17.4 Strategic initiatives
7.3.18 Famar Health Care Services
7.3.18.1 Company Overview
7.3.18.2 Product benchmarking
7.3.18.3 Strategic initiatives
7.3.19 Catalent Pharma Solutions
7.3.19.1 Company Overview
7.3.19.2 Financial performance
7.3.19.3 Product benchmarking
7.3.19.4 Strategic initiatives
7.3.20 West Pharmaceutical Services, Inc.
7.3.20.1 Company Overview
7.3.20.2 Financial performance
7.3.20.3 Product benchmarking
7.3.20.4 Strategic initiatives
Note: Product cover images may vary from those shown
  • Boehringer Ingelheim GmbH
  • Lonza
  • Grifols S.A
  • Jubilant Life Sciences Limited
  • Pfizer, Inc.
  • Charles River Laboratories International, Inc
  • Albany Molecular Research, Inc.
  • Covance, Inc. (Labcorp)
  • Iqvia
  • Baxter Biopharma Solutions
  • Aenova Holding GmbH
  • Vetter Pharma
  • Valeant Pharmaceuticals International Inc.
  • Ligand Pharmaceuticals, Inc.
  • Pharmaceutical Product Development, LLC
  • Recipharm Ab.
  • Abbvie, Inc.
  • Famar Health Care Services
  • Catalent Pharma Solutions
  • West Pharmaceutical Services, Inc.
Note: Product cover images may vary from those shown

Loading
LOADING...